|本期目录/Table of Contents|

[1]赖雪梅,黄金园,张海燕,等.个体化营养支持联合药物治疗多囊卵巢综合征的研究[J].医学研究与战创伤救治(原医学研究生学报),2021,23(01):32-35.[doi:10.3969/j.issn.1672-271X.2021.01.001]
 LAI Xue-mei,HUANG Jin-yuan,ZHANG Hai-yan,et al.Effect of individualized nutritional support combined with drug therapy on polycystic ovary syndrome[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(01):32-35.[doi:10.3969/j.issn.1672-271X.2021.01.001]
点击复制

个体化营养支持联合药物治疗多囊卵巢综合征的研究()

《医学研究与战创伤救治》(原医学研究生学报)[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年01期
页码:
32-35
栏目:
临床研究
出版日期:
2021-01-20

文章信息/Info

Title:
Effect of individualized nutritional support combined with drug therapy on polycystic ovary syndrome
作者:
赖雪梅黄金园张海燕钟荧
作者单位:400021重庆,重庆市妇幼保健院妇女保健科(赖雪梅、黄金园、张海燕、钟荧)
Author(s):
LAI Xue-mei HUANG Jin-yuan ZHANG Hai-yan ZHONG Ying
(Maternal and Child Health Hospital of Chongqing, Chongqing 400021,China)
关键词:
个体化营养药物治疗多囊卵巢综合征性激素
Keywords:
individualized nutrition drug therapy polycystic ovary syndrome sex hormone
分类号:
R711
DOI:
10.3969/j.issn.1672-271X.2021.01.001
文献标志码:
A
摘要:
目的分析个体化营养支持联合药物治疗多囊卵巢综合征(PCOS)的疗效,探讨PCOS个体化管理方案。方法选取重庆市妇幼保健院2017年4月至2018年4月收治的156例PCOS患者,采用随机数字表法分为个体化营养支持组(营养组)、对照组各78例,均给予炔雌醇环丙孕酮及二甲双胍治疗。对比2组患者治疗前、治疗6个月后的人体测量指标[体质量指数(BMI)、腰臀比及体脂率]、生化指标(糖脂代谢、性激素)变化,其中糖脂代谢指标包括空腹血糖(FPG)、胰岛素抵抗指数(HOMA-IR)及总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C),性激素指标包括卵泡刺激素(FSH)、黄体生成素(LH)及睾酮(T);以及治疗6个月后排卵率、妊娠率。结果2组治疗6个月后BMI、体脂率均较治疗前下降,营养组治疗6个月后BMI、体脂率分别为(24.28±1.43)kg/m2、(25.44±3.69)%,低于对照组同期水平(26.11±1.26)kg/m2、(26.71±3.28)%,差异均有统计学意义(P<0.05)。2组治疗6个月后FPG、HOMA-IR均较治疗前下降,HDL-C均较治疗前升高,营养组治疗6个月后FPG、HOMA-IR分别为(5.09±0.87)mmol/L、(4.26±1.08),低于对照组的(5.34±0.75)mmol/L、(5.37±0.99),HDL-C为(1.76±0.33)mmol/L,高于对照组同期水平(1.35±0.31)mmol/L,差异均有统计学意义(P<0.05)。2组治疗6个月后LH、T均较治疗前下降,营养组治疗6个月后LH、T为(5.71±1.26)mIU/mL、(15.23±2.71)nmol/L,低于对照组同期水平(6.17±0.95)mIU/mL、(18.81±2.62)nmol/L,差异均有统计学意义(P<0.05)。营养组治疗6个月后排卵率、妊娠率分别为65.38%、57.69%,均高于对照组的51.28%、44.87%,差异有统计学意义(P<0.05)。结论个体化营养支持联合药物治疗,对于改善PCOS患者体质、糖脂代谢、性激素水平,以及提高排卵率、妊娠率均有着积极意义。
Abstract:
ObjectiveTo analyze the effect of individualized nutritional support combined with drug therapy in the treatment of polycystic ovary syndrome (PCOS), and to explore the individualized management scheme of clinical PCOS.MethodsA total of 156 patients with PCOS admitted to our hospital from April 2017 to April 2018 were randomly divided into the observation group and the control group, 78 cases in each group. They were treated with cyproterone and metformin, and the patients in the observation group were treated with individualized nutrition support. The changes of anthropometric indexes, biochemical indexes (glucose and lipid metabolism, sex hormone), ovulation rate and pregnancy rate of the two groups before and 6 months after treatment were compared.ResultsThe BMI and body fat rate of the observation group were (24.28±1.43) kg/m2, (25.44±3.69) %, which were lower than that (26.11±1.26) kg/m2, (26.71±3.28) % of the control group at 6 months after treatment (P<0.05). FPG and HOMA-IR were decreased 6 months after treatment in the two groups, while HDL-C was increased. FPG and HOMA-IR in the observation group were (5.09±0.87) mmol/L, (4.26±1.08), which were lower than those in the control group (5.34±0.75) mmol/L, (5.37±0.99). And HDL-C was (1.76±0.33) mmol/L, which was higher than that (1.35±0.31) mmol/L in the control group at the same period (P<0.05). The LH and T in the observation group were (5.71±1.26) mIU/mL, (15.23±2.71) nmol/L, which were lower than those (6.17±0.95) mIU/mL, (18.81±2.62) nmol/L in the control group at the same time (P<0.05). The ovulation rate and pregnancy rate of the observation group after 6 months of treatment were 65.38% and 57.69%, which were higher than the control group (51.28% and 44.87%) (P<0.05).ConclusionIndividualized nutritional support combined with drug therapy has positive significance for improving the constitution, glucose and lipid metabolism, sex hormone level, ovulation rate and pregnancy rate of PCOS patients.

参考文献/References:

[1]Hartmann G, McEwen B. Insulin resistance and Polycystic ovary syndrome (PCOS): Part 2. Diet and Nutritional Medicine[J]. J Aust Tradit-Med Soc, 2019, 25(1): 18-22.
[2]Rodrigues A, Costa A, Campos DL, et al. Low validity of predictive equations for calculating resting energy expenditure in overweight and obese women with polycystic ovary syndrome[J]. J Hum Nutr Diet, 2018, 31(2): 266-275.
[3]周燕, 王玲, 姬旭慧, 等. 饮食干预配合药物治疗肥胖型多囊卵巢综合征的效果评价[J]. 中华健康管理学杂志, 2018, 12(1): 68-70.
[4]Feng W, Jia YY, Zhang DY, et al. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin[J]. Gynecol Endocrinol, 2016, 32(2): 147-150.
[5]Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)[J].Hum Reprod, 2004, 19(1): 41-47.
[6]中国超重肥胖医学营养治疗专家共识编写委员会. 中国超重/肥胖医学营养治疗专家共识(2016年版)[J]. 中华糖尿病杂志, 2016, 8(9): 525-540.
[7]冯麟增. 产超声诊断学[M]. 北京科学技术出版社, 1994: 59-63.
[8]Kite C, Lahart IM, Afzal I, et al. Exercise, or exercise and diet for themanagement of polycystic ovary syndrome: a systematic review and meta-analysis[J]. Syst Rev, 2019, 8(1): 51.
[9]华飞, 吕欣, 项守奎, 等. 多囊卵巢综合征患者血清骨钙素水平的变化[J]. 医学研究生学报, 2016, 29(6): 625-628.
[10]Carolo AL, Mendes MC, de Sá Rosa ACJ, et al. Nutritional counseling promotes changes in the dietary habits of overweight and obese adolescents with polycystic ovary syndrome[J].RBGO Gynecol Obstet, 2017, 39(12): 692-696.
[11]Kazemi M, McBreairty LE, Chizen DR, et al. A comparison of a pulse-based diet and the therapeutic lifestyle changes diet in combination with exercise and health counselling on the cardio-metabolic risk profile in women with polycystic ovary syndrome: a randomized controlled trial[J]. Nutrients, 2018, 10(10): 1387.
[12]Sundstrm Poromaa I, Mellembakken JR, Papunen LM, et al. Should we individualize lipid profiling in women with polycystic ovary syndrome?[J] Hum Reprod, 2016, 31(12): 2791-2795.
[13]王小红, 王志君, 缪铃, 等. 维生素D联合二甲双胍对多囊卵巢综合征患者排卵及子宫内膜容受性的影响研究[J]. 东南国防医药, 2015, 17(2): 142-145.
[14]林金芳. 关于多囊卵巢综合征患者的生活方式干预[J]. 中华生殖与避孕杂志, 2019, 39(3): 173-176.
[15]Gde F, Yücesoy F, Sagˇlam A, et al. Serum procalcitonin and proinflammatory markers in polycystic ovary syndrome[J]. Gynecol ObstetReprod Med, 2017, 23(1): 20-25.
[16]朱璇. 营养干预对肥胖型多囊卵巢综合症患者抗苗勒管激素和受孕率影响的研究[J]. 中国性科学, 2019, 28(8): 80-83.
[17]Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J]. Hum Reprod, 2018, 33(9): 1602-1618.
[18]Boyd M, Ziegler J. Polycystic Ovary Syndrome, Fertility, Diet, and Lifestyle Modifications: A Review of the Current Evidence[J]. Top Clin Nutr, 2019, 34(1): 14-30.

相似文献/References:

[1]曹清心.注意缺陷多动障碍药物治疗进展[J].医学研究与战创伤救治(原医学研究生学报),2008,10(02):122.
[2]程木,何芳,张琰,等.奥密克戎感染高龄重症患者药物治疗的护理体会[J].医学研究与战创伤救治(原医学研究生学报),2023,25(3):312.[doi:10.3969/j.issn.1672-271X.2023.03.018]

备注/Memo

备注/Memo:
基金项目:重庆市卫生计生委医学科研项目(2017MSXM108)
更新日期/Last Update: 2021-01-26